Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Current opinion in genetics & development - 1 Feb 2012

Yauch Robert L, Settleman Jeff

Abstract excerpt

Substantial recent progress has been reported in the context of implementing 'personalized' cancer medicine, informed by tumor genotyping. The recent FDA approvals of crizotinib, an ALK kinase inhibitor that has yielded significant clinical benefit in ALK-translocated lung cancers, and vemurafenib, a BRAF-selective kinase inhibitor that has demonstrated dramatic clinical efficacy in BRAF mutant melanoma patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to ALK gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Genome

Share to Genotype

Share to Melanoma and MAPK Pathways

Share to Neoplasms

Source

Identifiers

PMID: 22321987
DOI: 10.1016/j.gde.2012.01.003

Genes

ALK
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.PMID 22321987Read ↗

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncologySemantic proximity Read ↗

Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop.Semantic proximity Read ↗

Designing Transformative Clinical Trials in the Cancer Genome EraSemantic proximity Read ↗

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.Semantic proximity Read ↗

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.Semantic proximity Read ↗

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

Exploiting genetic complexity in cancer to improve therapeutic strategies.Semantic proximity Read ↗

BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Semantic proximity Read ↗

Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted TherapySemantic proximity Read ↗

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity Read ↗

Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular TherapeuticsSemantic proximity Read ↗

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.